This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The application of biomarkers to clinical Alzheimer disease (AD) research has transformed the way we think about the disorder. Probable AD was defined as a clinical syndrome, generally amnestic, that progressed to global dementia. Poor prediction of the underlying pathology has made it clear that this approach is inadequate, particularly for patients with atypical or mild symptoms. The recent proposal of a biomarker-based framework for diagnosis has moved our thinking about AD from the syndromic to the biological.1 In this framework, evidence of β-amyloid and tau deposition in the brain constitutes AD, regardless of clinical presentation. Using this biomarker approach with PET imaging, Therriault et al.2 report in this issue of Neurology® the patterns of β-amyloid (denoted A) and tau (denoted T) PET abnormalities in a group of persons with cognitive impairment recruited from a dementia-specialty clinic population. Their observations allow us to judge the added value of the PET biomarkers and to compare clinical and biomarker diagnoses.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 304
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.